



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James P. HOEFFLER *et al.*
Title: SINGLE CHAIN MONOCLONAL ANTIBODY FUSION REAGENTS THAT REGULATE TRANSCRIPTION *IN VIVO*
Application No.: 09/939,769
Filing Date: August 28, 2001
Examiner: Stephen L. Rawlings
Art Unit: 1642

15/2
KO
6-303

**AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR SEQUENCE LISTING UNDER 37 C.F.R. § 1.821-1.825**

Mail Stop NON-FEE AMENDMENT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

This is a reply to the Office communication mailed April 29, 2003, in the above-referenced application. Prior to reconsideration, Applicants request that the Office enter the following amendments.

In the Specification

Please amend the specification as follows. In accordance with 37 CFR § 1.121, a marked up version showing the changes in the specification is attached.

Page 7, delete paragraph starting at line 3 ending at line 5 and replace this paragraph with the following.

FIG. 2 Shows schematic representations of example intracellular targeting sequences (DPKKRKV, SEQ ID NO: 92; SEKDEL, SEQ ID NO: 93; MSVLTPLLRGLTGSARRLPVRAKIHSL, SEQ ID NO:1; and METDLLLVLLLWVPGSTGD, SEQ ID NO:2, respectively) for use with single chain

51